Antagonism of cannabinoid receptor 2 pathway suppresses IL-6-induced immunoglobulin IgM secretion

BMC Clinical Pharmacology

Xiang-Qun Xie²  Christine A Milcarek²  Rentian Feng¹ 

[1] Department of Pharmaceutical Sciences, Computational Chemical Genomics Screening Center, University of Pittsburgh School of Pharmacy, Pittsburgh, PA, USA;University of Pittsburgh Cancer Institute, Clinical and Translational Science Institute, Pittsburgh, PA, USA

关键词: STAT3;    Liands;    Cannabinoid receptor 2;    IgM;    B cells;   

Others  :  860319
DOI  :  10.1186/2050-6511-15-30

 received in 2013-10-07, accepted in 2014-04-21,  发布年份 2014

【 摘 要 】

Background

Cannabinoid receptor 2 (CB2) is expressed predominantly in the immune system, particularly in plasma cells, raising the possibility that targeting the CB2 pathway could yield an immunomodulatory effect. Although the role of CB2 in mediating immunoglobulin class switching has been reported, the effects of targeting the CB2 pathway on immunoglobulin secretion per se remain unclear.

Methods

Human B cell line SKW 6.4, which is capable of differentiating into IgM-secreting cells once treated with human IL-6, was employed as the cell model. SKW 6.4 cells were incubated for 4 days with CB2 ligands plus IL-6 (100 U/ml). The amount of secreted IgM was determined by an ELISA. Cell proliferation was determined by the ³H-Thymidine incorporation assay. Signal molecules involved in the modulation of IgM secretion were examined by real-time RT-PCR and Western blot analyses or by using their specific inhibitors.

Results

We demonstrated that CB2 inverse agonists SR144528 and AM630, but not CB2 agonist HU308 or CB1 antagonist SR141716, effectively inhibited IL-6-induced secretion of soluble IgM without affecting cell proliferation as measured by thymidine uptake. SR144528 alone had no effects on the basal levels of IgM in the resting cells. These effects were receptor mediated, as pretreatment with CB2 agonist abrogated SR144528-mediated inhibition of IL-6 stimulated IgM secretion. Transcription factors relevant to B cell differentiation, Bcl-6 and PAX5, as well as the protein kinase STAT3 pathway were involved in the inhibition of IL-6-induced IgM by SR144528.

Conclusions

These results uncover a novel function of CB2 antagonists and suggest that CB2 ligands may be potential modulators of immunoglobulin secretion.

【 授权许可】

   
2014 Feng et al.; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA, Felder CC, Herkenham M, Mackie K, Martin BR, Mechoulam R, Pertwee RG: International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 2002, 54:161-202.
• [2]Lunn CA, Reich EP, Bober L: Targeting the CB2 receptor for immune modulation. Expert Opin Ther Targets 2006, 10:653-663.
• [3]Galiegue S, Mary S, Marchand J, Dussossoy D, Carriere D, Carayon P, Bouaboula M, Shire D, Le Fur G, Casellas P: Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem 1995, 232:54-61.
• [4]Christensen R, Kristensen PK, Bartels EM, Bliddal H, Astrup A: Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet 2007, 370:1706-1713.
• [5]Manera C, Benetti V, Castelli MP, Cavallini T, Lazzarotti S, Pibiri F, Saccomanni G, Tuccinardi T, Vannacci A, Martinelli A, Ferrarini PL: Design, synthesis, and biological evaluation of new 1,8-naphthyridin-4(1H)-on-3-carboxamide and quinolin-4(1H)-on-3-carboxamide derivatives as CB2 selective agonists. J Med Chem 2006, 49:5947-5957.
• [6]Sarfaraz S, Adhami VM, Syed DN, Afaq F, Mukhtar H: Cannabinoids for cancer treatment: progress and promise. Cancer Res 2008, 68:339-342.
• [7]Eisenstein TK, Meissler JJ, Wilson Q, Gaughan JP, Adler MW: Anandamide and Delta9-tetrahydrocannabinol directly inhibit cells of the immune system via CB2 receptors. J Neuroimmunol 2007, 189:17-22.
• [8]Klein TW: Cannabinoid-based drugs as anti-inflammatory therapeutics. Nat Rev Immunol 2005, 5:400-411.
• [9]Ashton JC, Glass M: The cannabinoid CB2 receptor as a target for inflammation-dependent neurodegeneration. Curr Neuropharmacol 2007, 5:73-80.
• [10]Schuehly W, Paredes JM, Kleyer J, Huefner A, Anavi-Goffer S, Raduner S, Altmann KH, Gertsch J: Mechanisms of osteoclastogenesis inhibition by a novel class of biphenyl-type cannabinoid CB(2) receptor inverse agonists. Chem Biol 2011, 18:1053-1064.
• [11]Ofek O, Karsak M, Leclerc N, Fogel M, Frenkel B, Wright K, Tam J, Attar-Namdar M, Kram V, Shohami E, Mechoulam R, Zimmer A, Bab I: Peripheral cannabinoid receptor, CB2, regulates bone mass. Proc Natl Acad Sci U S A 2006, 103:696-701.
• [12]Yang P, Wang L, Xie XQ: Latest advances in novel cannabinoid CB(2) ligands for drug abuse and their therapeutic potential. Future Med Chem 2012, 4:187-204.
• [13]Rinaldi-Carmona M, Barth F, Millan J, Derocq JM, Casellas P, Congy C, Oustric D, Sarran M, Bouaboula M, Calandra B, Portier M, Shire D, Brelière JC, Le Fur GL: SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. J Pharmacol Exp Ther 1998, 284:644-650.
• [14]Daaka Y, Friedman H, Klein TW: Cannabinoid receptor proteins are increased in Jurkat, human T-cell line after mitogen activation. J Pharmacol Exp Ther 1996, 276:776-783.
• [15]Cabral GA, Griffin-Thomas L: Emerging role of the cannabinoid receptor CB2 in immune regulation: therapeutic prospects for neuroinflammation. Expert Rev Mol Med 2009, 11:e3.
• [16]Agudelo M, Newton C, Widen R, Sherwood T, Nong L, Friedman H, Klein TW: Cannabinoid receptor 2 (CB2) mediates immunoglobulin class switching from IgM to IgE in cultures of murine-purified B lymphocytes. J Neuroimmune Pharmacol 2008, 3:35-42.
• [17]Bouaboula M, Dussossoy D, Casellas P: Regulation of peripheral cannabinoid receptor CB2 phosphorylation by the inverse agonist SR 144528. Implications for receptor biological responses. J Biol Chem 1999, 274:20397-20405.
• [18]Sherwood TA, Nong L, Agudelo M, Newton C, Widen R, Klein TW: Identification of transcription start sites and preferential expression of select CB2 transcripts in mouse and human B lymphocytes. J Neuroimmune Pharmacol 2009, 4:476-488.
• [19]Kawamoto T, Gohda E, Iji H, Fujiwara M, Yamamoto I: SKW 6.4 cell differentiation induced by interleukin 6 is stimulated by butyrate. Immunopharmacology 1998, 40:119-130.
• [20]Kishimoto T, Hirano T, Kuritani T, Yamamura Y, Ralph P, Good RA: Induction of IgG production in human B lymphoblastoid cell lines with normal human T cells. Nature 1978, 271:756-758.
• [21]Goldstein H, Koerholz D, Chesky L, Fan XD, Ambrus JL Jr: Divergent activities of protein kinases in IL-6-induced differentiation of a human B cell line. J Immunol 1990, 145:952-961.
• [22]Tamura K, Woo J, Bakri MT, Thomson AW: Brequinar sodium inhibits interleukin-6-induced differentiation of a human B-cell line into IgM-secreting plasma cells. Immunology 1993, 79:587-593.
• [23]Feng R, Anderson G, Xiao G, Elliott G, Leoni L, Mapara MY, Roodman GD, Lentzsch S: SDX-308, a nonsteroidal anti-inflammatory agent, inhibits NF-{kappa}B activity, resulting in strong inhibition of osteoclast formation/activity and multiple myeloma cell growth. Blood 2007, 109:2130-2138.
• [24]Feng R, Li SR, Lu CS, Andreas C, Stolz DB, Mapara MY, Lentzsch S: Targeting the Microtubular Network as a New Antimyeloma Strategy. Mol Cancer Ther 2011, 10:1886-1896.
• [25]Genestier L, Taillardet M, Mondiere P, Gheit H, Bella C, Defrance T: TLR agonists selectively promote terminal plasma cell differentiation of B cell subsets specialized in thymus-independent responses. J Immunol 2007, 178:7779-7786.
• [26]McClure EA, North CM, Kaminski NE, Goodman JI: Changes in DNA methylation and gene expression during 2,3,7,8-tetrachlorodibenzo-p-dioxin-induced suppression of the lipopolysaccharide-stimulated IgM response in splenocytes. Toxicol Sci 2011, 120:339-348.
• [27]Korholz D, Gerdau S, Enczmann J, Zessack N, Burdach S: Interleukin 6-induced differentiation of a human B cell line into IgM-secreting plasma cells is mediated by c-fos. Eur J Immunol 1992, 22:607-610.
• [28]Basu S, Ray A, Dittel BN: Cannabinoid receptor 2 is critical for the homing and retention of marginal zone B lineage cells and for efficient T-independent immune responses. J Immunol 2011, 187:5720-5732.
• [29]Feng B, Cheng S, Pear WS, Liou HC: NF-κB inhibitor blocks B cell development at two checkpoints. Med Immunol 2004, 3:1. BioMed Central Full Text
• [30]Lee H, Herrmann A, Deng JH, Kujawski M, Niu G, Li Z, Forman S, Jove R, Pardoll DM, Yu H: Persistently activated Stat3 maintains constitutive NF-kappaB activity in tumors. Cancer Cell 2009, 15:283-293.
• [31]Rodriguez-Berriguete G, Prieto A, Fraile B, Bouraoui Y, de Bethencourt FR, Martinez-Onsurbe P, Olmedilla G, Paniagua R, Royuela M: Relationship between IL-6/ERK and NF-kappaB: a study in normal and pathological human prostate gland. Eur Cytokine Netw 2010, 21:241-250.
• [32]Marshall AJ, Niiro H, Yun TJ, Clark EA: Regulation of B-cell activation and differentiation by the phosphatidylinositol 3-kinase and phospholipase Cgamma pathway. Immunol Rev 2000, 176:30-46.
• [33]Elsawa SF, Novak AJ, Ziesmer SC, Almada LL, Hodge LS, Grote DM, Witzig TE, Fernandez-Zapico ME, Ansell SM: Comprehensive analysis of tumor microenvironment cytokines in Waldenstrom macroglobulinemia identifies CCL5 as a novel modulator of IL-6 activity. Blood 2011, 118:5540-5549.
• [34]Daeipour M, Kumar G, Amaral MC, Nel AE: Recombinant IL-6 activates p42 and p44 mitogen-activated protein kinases in the IL-6 responsive B cell line, AF-10. J Immunol 1993, 150:4743-4753.
• [35]Fornek JL, Tygrett LT, Waldschmidt TJ, Poli V, Rickert RC, Kansas GS: Critical role for Stat3 in T-dependent terminal differentiation of IgG B cells. Blood 2006, 107:1085-1091.
• [36]Faris M, Kokot N, Stahl N, Nel AE: Involvement of Stat3 in interleukin-6-induced IgM production in a human B-cell line. Immunology 1997, 90:350-357.
• [37]Karras JG, McKay RA, Lu T, Pych J, Frank DA, Rothstein TL, Monia BP: STAT3 regulates the growth and immunoglobulin production of BCL(1) B cell lymphoma through control of cell cycle progression. Cell Immunol 2000, 202:124-135.
• [38]Lin KI, Tunyaplin C, Calame K: Transcriptional regulatory cascades controlling plasma cell differentiation. Immunol Rev 2003, 194:19-28.
• [39]Bhattacharya S, Conolly RB, Kaminski NE, Thomas RS, Andersen ME, Zhang Q: A bistable switch underlying B-cell differentiation and its disruption by the environmental contaminant 2,3,7,8-tetrachlorodibenzo-p-dioxin. Toxicol Sci 2010, 115:51-65.
• [40]Tunyaplin C, Shaffer AL, Angelin-Duclos CD, Yu X, Staudt LM, Calame KL: Direct repression of prdm1 by Bcl-6 inhibits plasmacytic differentiation. J Immunol 2004, 173:1158-1165.